Vertex Expands Gene Therapy Footprint with CRISPR Therapeutics and Exonics Deals
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 6 (Table of Contents)
Published: 17 Jun-2019
DOI: 10.3833/pdr.v2019.i6.2433 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a move to enhance its gene editing capabilities, Vertex Pharmaceuticals has agreed to both expand its collaboration with CRISPR Therapeutics and acquire Exonics Therapeutics for a combined US$420 M upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS